1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 107 pages

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Neutropenia (Oncology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 4, 5, 8, 1, 13, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chemotherapy Induced Neutropenia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Neutropenia - Overview
Chemotherapy Induced Neutropenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chemotherapy Induced Neutropenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
Apotex Inc
Biocon Ltd
Biogenomics Ltd
Bolder Biotechnology Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cinfa Biotech SL
Dr. Reddy's Laboratories Ltd
Gene Techno Science Co Ltd
Generon (Shanghai) Corp Ltd
Genexine Inc
GlycoMimetics Inc
Hanmi Pharmaceuticals Co Ltd
Mycenax Biotech Inc
Myelo Therapeutics GmbH
Nohla Therapeutics Inc
Octapharma AG
Pfenex Inc
Pfizer Inc
Reliance Life Sciences Pvt Ltd
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd
Chemotherapy Induced Neutropenia - Drug Profiles
BBT-007 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BBT-015 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
BBT-018 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Cell Therapy for Chemotherapy Induced Neutropenia - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
EC-18 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
eflapegrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
F-627 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GMI-1271 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GW-003 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GXG-3 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HSA-GCSF - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Myelo-001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
TXA-302 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
WBI-2100 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
YPEG-Filgrastim - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Chemotherapy Induced Neutropenia - Dormant Projects
Chemotherapy Induced Neutropenia - Discontinued Products
Chemotherapy Induced Neutropenia - Product Development Milestones
Featured News and Press Releases
Feb 16, 2017: U.S. FDA Accepts Biologics License Application for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review
Dec 05, 2016: Spectrum Pharmaceuticals Highlights Four Abstracts on ROLONTIS (eflapegrastim) at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
Dec 02, 2016: Cinfa Biotech publishes clinical data abstract at the 58th American Society of Hematology Annual Meeting 2016
Sep 26, 2016: Cinfa Biotech starts second clinical study of pegfilgrastim biosimilar candidate B12019
Jul 04, 2016: Cinfa Biotech announces positive top-line clinical data of pegfilgrastim biosimilar candidate B12019
Dec 16, 2015: Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 - A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China
May 10, 2011: Dr Reddy's Launches Pegfilgrastim In India Under Brand Name Peg-grafeel
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients
Dec 08, 2010: Generon Presents Poster On F-627 At 52nd Annual Meeting Of American Society Of Hematology
Nov 22, 2010: Generon Completes Dosing In Phase I Study Of F-627 In Australia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Apotex Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Biogenomics Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Cinfa Biotech SL, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Genexine Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Myelo Therapeutics GmbH, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Octapharma AG, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Pfenex Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2017
Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2017
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017
Chemotherapy Induced Neutropenia - Dormant Projects, H1 2017 (Contd..1), H1 2017
Chemotherapy Induced Neutropenia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.